The treatment of staphylococcal infections with special reference to pharmacokinetic, pharmacodynamic and pharmacoeconomic considerations.

摘要: The choice of antibiotics for the treatment staphylococcal infections depends to a high degree on susceptibility patterns in hospital question. These may be highly variable and considerable differences between countries hospitals exist. insight into pharmacodynamic aspects antimicrobial agents has increased considerably last 5 years, resulting new treatments, such as once daily administration aminoglycosides continuous infusion betalactam antibiotics. antibiotic policy Dutch is discussed. In most Western with relatively low incidence MRSA, penicillin–derivatives, flucloxacillin (or cloxacillin, methicillin nafcillin) will drug choice, because their good in-vitro activity, toxicity, clinical efficacy cost. If MRSA increases, drugs glycopeptides more importance. This course have clear economic impact, both vancomycin teicoplanin are expensive than oral not possible. Pharmacoeconomic also play role. As rule, intravenous formulations. Before can recommended, reliable absorption, seriously ill patients, must been demonstrated. Other that influence cost therapy stay possibility outpatient treatment.